Trellus Health plc

("Trellus Health", the "Company" or the "Group")

Business update

LONDON, U.K. AND NEW YORK, U.S. (4 March 2025). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, provides a business update.

In September 2024, within Trellus Health's interim results, the Company stated its cash runway had been extended into late Q3 2025. As of 28 February 2025, the Company had net cash of $3.4 million, with the Company's current cash runway extending to the end of October 2025, on current contracted revenue levels.

In January 2025, the Company announced it had entered into an agreement with Johnson & Johnson Health Care Systems Inc. ("J&J") to support a pilot in the US to assess the potential for the Trellus Elevate program to support patients with moderately to severely active inflammatory bowel disease (IBD). The one-year collaboration will provide eligible patients prescribed J&J therapy access to Trellus Elevate. The Company is collaborating closely with J&J to finalise preparations for the program launch.

In Trellus Health's interim results in September 2024, the Company announced that the enrollment phase of its business-to-business-to-consumer ("B2B2C") agreement signed with a large US national health plan had been extended. The enrollment phase has now concluded, with the program now closed to new members. Whilst, as previously announced, the number of enrolled members is limited, positive outcomes from these members have been seen. For those who participated, there was an 89% increase in resilience-associated behaviour upon completion of the program, and 78% reported feeling more confident about managing their condition at three months. Trellus Health will continue to service those members active on the platform until the earlier of either the completion of the term of the contract in November 2025 or until all current members have completed their personal resilience program.

In Trellus Health's interim results in September 2024, the Company also referenced two licensing agreements with pharmaceutical industry partners for elements of its resilience-based methodology. One agreement is for the use of resilience-based assessments in the setting of a clinical trial and the other is for the use of customised self-efficacy educational content. These agreements have generated modest revenue as expected and, along with the J&J collaboration, highlight the potential value of the Company's proprietary resilience-based platform, programs and assessments to pharma clients.

The Company remains focused on demonstrating commercial progress and pursuing potential partnership agreements, particularly within its pharmaceutical verticals, to enhance patient support for approved therapies and to support clinical trials where low resilience contributes to higher attrition rates and extended completion timelines.

The Company will provide its full year results for the year ending 31 December 2024 no later than 30 June 2025 and provide further updates to the market in due course as appropriate.

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "We kicked off 2025 with the signing of a key pilot agreement with J&J and have made significant progress on implementation in preparation for launch. The pharmaceutical sector remains a core strategic focus for us, as we believe our resilience-based methodology delivers meaningful value to both our partners and individuals managing chronic conditions. We are working hard to achieve further commercial and strategic progress and will provide further updates to the market in due course as appropriate."

For further information please contact:

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com